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Running Title 




Gadolinium deposition in dentate nucleus (DN) has been reported after serial administration of gadolinium-
based contrast agents (GBCAs). Gadolinium complexes have paramagnetic properties, therefore, we evaluated 
susceptibility changes of gadolinium deposition in dentate nucleus (DN), using quantitative susceptibility 
mapping (QSM) for patients after serial administration of GBCAs.  
Materials and Methods 
48 patients with brain tumors, who had had serial GBCA administrations (GBCA group), and 48 healthy 
volunteers without any history of GBCA administrations (non-GBCA group) were enrolled to this study. 
Susceptibility values in DN on QSM and DN-to-cerebellum signal intensity ratios on unenhanced T1-weighted 
images (T1 ratios) on 3T were analyzed. The relationship between the number of times of GBCA 
administrations and susceptibility values or T1 ratios were evaluated in GBCA group. 
Results 
Susceptibility values at DN in GBCA group were 0.107 ±0.029 ppm, and significantly higher than those of 
non-GBCA group (0.079 ±0.025 ppm) (P<0.0001). T1 ratios in DN of GBCA group was 1.059 ±0.070, and 
also significantly higher than that of non-GBCA group (0.993 ±0.016) (P<0.0001). Spearman rank correlation 
coefficient between susceptibility values and the number of times of linear GBCA administration showed a 
modest significant correlation (ρ=0.45, P=0.0015). There is good correlation between T1 ratios and the 
number of times of linear GBCA administration as reported previously (ρ=0.76, P<0.0001). 
Conclusion 
Susceptibility values on QSM in DN of GBCA group, after serial administration of GBCAs, were significantly 
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 Gadolinium-based contrast agents (GBCAs) have been widely used for contrast-material-enhanced 
magnetic resonance (MR) imaging. It is well known that the blood brain barrier (BBB) failure leads to the 
leakage of the GBCAs and high signal intensity on T1-weighted images in the central nervous system (CNS), 
GBCAs have been frequently used for evaluation of the central nervous system diseases such as brain tumors 
and demyelinating diseases. In addition to the alert of nephrogenic systemic fibrosis (NSF) due to free 
gadolinium deposition to cutaneous tissues, gadolinium accumulation in the dentate nucleus (DN) has gained 
attention after recent reports of Kanda, et al,1-3 Errante, et al,4 McDonald, et al,5 Radbruch, et al,6 Quattrocchi, 
et al,7,8 and Ramalho, et al.9 GBCAs are synthesized as complexes, using linear or macrocyclic chelates, and 
linear GBCAs have reported to be associated with T1 hyperintensity in DN.3 Most recent studies have focused 
T1 shortening effect of gadolinium in the DN on T1-weighted images qualitatively,2-6,9 however, susceptibility 
changes on quantitative susceptibility mapping (QSM) due to paramagnetic effect of gadolinium may provide 
a more quantitative assessment. 
 Magnetic susceptibility is conventionally evaluated on T2*-weighted imaging qualitatively on MR,10 
but QSM is a robust technique due to its direct measurement of voxel-wise tissue magnetic susceptibility from 
phase images.11-15 Based on recent studies, QSM can provide in vivo quantitative susceptibility values.16,17 
QSM has been applied to study hemorrhages,18,19 multiple sclerosis,20,21 and neurodegenerative diseases such 
as Alzheimer disease22 and Parkinson disease.23,24 In these diseases, iron accumulation or demyelination is 
supposed to occur in brain, which consequently increase magnetic susceptibility values.18-21,25 
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 In this study, we hypothesized that serial usage of GBCA will increase magnetic susceptibility values 
in DN of humans on QSM images. Serial usage of GBCA was performed for limited purposes such as follow-
up studies of patients with brain tumors and multiple sclerosis. Therefore, we retrospectively investigated 
susceptibility values in DN of brain tumor patients who had serial GBCA administration in comparison with 
healthy volunteers who had no history of GBCA administration 
 
MATERIALS AND METHODS 
Subjects 
This single-center, retrospective observational study was performed after institutional review board 
approval, with waiver of the informed consent requirement. We assessed 53 consecutive patients with brain 
tumors since April 2014, whose original phase images of three-dimensional (3D) gradient-echo sequence were 
archived . 5 patients were excluded because of whole brain radiotherapy, or tumor-selective radiation therapy 
that included the DN within the radiation field, renal dysfunction. In total, 48 patients were finally enrolled in 
this study (GBCA group). Most patients underwent several MR scans with GBCA administration (linear and/or 
macrocyclic GBCA). The number of GBCA administration including linear and macrocyclic GBCA were 
abstracted from medical charts. GBCA of 0.1 mmol per kilogram of the patient’s body weight was injected 
for each scan. Forty-eight healthy volunteers without any history of GBCA-administration were recruited in 
order to for a comparison group for QSM, with IRB approval and written informed consent (non-GBCA group).  
Images acquisition 
 All the subjects had MRI examinations on 3T MR scanners (Magnetom Skyra or Trio, Siemens, 
Erlangen, Germany) with a 32-channel head coil. Our standard MR imaging protocol included a three-
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dimensional (3D) axial gradient-echo sequence (repetition time (TR) / echo time (TE) / echo spacing (ΔTE), 
55 ms / 3.6 - 45.0 ms / 5.91 ms; field of view (FOV), 240 × 240 mm; resolution, 0.9 × 0.9 × 2.0 mm), a T2-
weighted spin-echo sequence (TR/TE, 3200/79 ms; FOV, 185 × 220 mm; resolution, 0.5 × 0.5 × 3.0 mm), a 
fluid-attenuated inversion-recovery sequence (TR/TE, 12000/100 ms; inversion time (TI), 100 ms; FOV, 178 
× 220 mm; resolution, 0.7 × 0.7 × 3.0 mm), and a 3D sagittal T1-weighted sequence (volume-interpolated 
breath-hold examination, or VIBE: TR/TE, 6.0 ms/2.29 ms; flip angle, 15 °; FOV, 230 × 230 mm; resolution, 
0.9 × 0.9 × 0.9 mm, or magnetization-prepared rapid gradient-echo, or MPRAGE: TR/TE/TI, 1900 ms /2.58 
ms /900 ms; flip angle, 9 °; FOV, 230 × 230 mm; resolution, 0.9 × 0.9 × 0.9 mm). 3D sagittal T1-weighted 
images were reformatted to axial planes parallel to the axial images. 
QSM analysis 
 QSM calculation was conducted from the magnitude and phase images of the gradient echo images 
by using STI Suite version 2.10 (http://people.duke.edu/~cl160/). We first performed phase unwrapping and 
background phase removal using the sophisticated harmonic artifact reduction for phase data with a variable 
radius of the spherical kernel at the brain boundary (V-SHARP method).26,27 During this process, binary brain 
masks, created from the magnitude image by BET tool, were applied to facilitate the removal of background 
phase.28 After background phase removal, a susceptibility map was reconstructed from the resulting local 
tissue phase image by solving an inverse problem using the algorithm for sparse linear equations and sparse 
least squares (iLSQR method).26 
ROI analysis 
 A region of interest (ROI) study was performed by two board certified neuroradiologists (T.H., 8 
years of experience, Y.F., 18 years of experience) by manual placement of ROIs of DN and white matter in 
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the right cerebellar hemisphere on both T1-weigheted image and QSM image using the ImageJ software 
(National Institutes of Health, Bethesda, MD) (Fig. 1).2,3 ROI placement was agreed on by consensus, and 
ROI measurement was conducted once. In general, QSM images delineate DN very well in both groups, 
however, it is difficult to recognize DN on T1-weighted images for non-GBCA group, therefore, ROIs were 
placed by referring to QSM images. The mean of the susceptibility values of DN were measured and T1 ratios 
were defined as follows: mean values of DN divided by those of the cerebellar white matter on T1-weighted 
images.  
Statistics  
 We performed an unpaired t test with the Welch correlation to assess the difference of susceptibility 
values and T1 ratios of DN between the followings: (i) GBCA group (patients) vs. non-GBCA group (healthy 
volunteers), (ii) only macrocyclic GBCA administration in GBCA group vs. non-GBCA group, (iii) only linear 
GBCA or both linear and macrocyclic GBCA administrations in GBCA group vs. non-GBCA group. 
Nonparametric Spearman rank correlation coefficient was analyzed for the followings: (i) susceptibility values 
or T1 ratios vs. the number of times of linear GBCA administration, (ii) susceptibility values and T1 ratios in 
non-GBCA group vs. subjects’ age. All the statistical analyses were conducted using MedCalc version 13.3 
(MedCalc Software bvba, Ostend, Belgium). P values of less than .05 indicated a statistically significant 
difference.  In the first place, multiple regression analysis was conducted with the following variables 
concerning the effect on the susceptibility values: the times of linear GBCA administrations, mean intervals, 
median intervals, last intervals, all periods. None of these variables except the times of the linear GBCA 
administrations (P = 0.0066), therefore, in the next step, we adopted Spearman Rank correlation coefficient 





The subjects’ characteristics were shown in Table 1. The age distribution between GBCA group and 
non-GBCA group was not significantly different (P = 0.382). No patient received double-dose or triple-dose 
GBCA administration The median number of times of GBCA administration among GBCA group was 9.5 
(4.75 -21, 25th-75th percentile, 1 - 62; range of the number). Both linear type and macrocyclic type GBCA had 
been administered to the same patients with long-term follow-up because linear GBCA had been used for most 
of gadolinium enhanced studies before NSF problem was publicly known. The median number of times of 
linear type GBCA administration was 5 (1 - 12.5, 0 - 48) (n = 41), and that of macrocyclic GBCAs 
administration was 4 (1 - 7, 0 - 39) (n = 43). Among them, the number of macrocyclic GBCAs administration 
without any linear GBCA administration was 1 (1 - 2, 1 - 7) (n = 7). 
Susceptibility value and T1 ratio between GBCA and non-GBCA group 
The susceptibility values at DN in GBCA group were significantly higher than those of non-GBCA 
group (mean ± S.D., GBCA group, 0.107 ± 0.029 ppm; non-GBCA group, 0.079 ± 0.025 ppm, P < 0.0001) 
(Fig. 2). T1 ratios at DN in GBCA group were also significantly higher than that in non-GBCA group (GBCA 
group, 1.059 ± 0.070; non-GBCA group, 0.993 ± 0.016, P < 0.0001) (Fig. 3). 
Susceptibility values and T1 ratios for linear GBCA administration 
Among all the subjects of GBCA group and non-GBCA group (n = 48), Spearman rank correlation 
coefficient between susceptibility values and the number of times of linear GBCA administration showed a 
modest but significant correlation (ρ = 0.45, P = 0.0015) (Fig.4). On the other hand, there was a good 
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correlation between T1 ratios and the number of times of linear GBCA administration (ρ = 0.76, P < 0.0001) 
(Fig. 5). Spearman rank correlation coefficient analysis between susceptibility values and T1 ratios showed 
weak correlation (ρ = 0.53, P = 0.0001) (Fig. 6). 
Susceptibility values and T1 ratios for macrocyclic GBCA administration and linear GBCA administration. 
The mean susceptibility values in the DN of the patients who had only macrocyclic GBCA 
administration (n = 7) was 0.087 ± 0.019 ppm; the mean T1 ratio was 0.979 ± 0.031. There was no significant 
difference of susceptibility values (P = 0.348) or T1 ratios (P = 0.745) between macrocyclic GBCA-only 
group non-GBCA group. The mean susceptibility value in the DN of those who had only linear GBCA (n = 
5) or both linear and macrocyclic GBCA administration (n = 36) was 0.111 ± 0.029 ppm; the mean T1 ratio 
was 1.070 ± 0.069. There is significant difference of susceptibility values (P < 0.0001) and T1 ratio (P < 
0.0001) between linear or both linear and macrocyclic GBCA group and non-GBCA group. 
Susceptibility values and T1 ratios in non-GBCA group in comparison with subjects’ age. 
Susceptibility values have weak correlation between subjects’ age in non-GBCA group showed weak 
correlation (ρ = 0.38, P = 0.0074), and T1 ratios have also weak negative correlation (ρ = -0.331, P = 0.0217). 
 
DISCUSSON 
 Our analyses have shown that susceptibility values in DN of GBCA group (tumor patients group after 
serial GBCA administrations) were significantly higher than those of non-GBCA group (healthy controls) and 
T1 ratios of GBCA group are significantly higher than those of non-GBCA group. In the current study, we 
focused on the serial injection of GBCA and gadolinium deposition in DN as indicated by previous reports.1,5 
The results of T1 ratios are consistent with previous reports1,5 and we again confirmed T1 hyperintensity due 
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to gadolinium deposition after serial GBCA administrations.  
 DN is known to have rich iron content,29 and high susceptibility in DN has been reported.30 
Gadolinium is a strong paramagnetic substance with a molar susceptibility of 325 ppm·L/mol. Therefore, 
theoretically susceptibility values in DN should elevate when the T1 ratios shows gadolinium deposition in 
DN after serial GBCA administrations. The results of higher susceptibility values in DN of GBCA group than 
non-GBCA group supports our initial hypothesis that QSM can be a biomarker of gadolinium deposition in 
vivo in addition to T1-weghted images. 
 In recent study, macrocyclic GBCA shows less or no abnormal deposition in the DN than linear 
GBCA, which supported that macrocyclic GBCA has excellent chemical stability without dissociation of free 
gadolinium.3 In this study, the number of GBCA group with only macrocyclic GBCA was quite small, but the 
susceptibility values were close to those of non-GBCA group and had no significant difference. On the contrary, 
the susceptibility values of GBCA group, with previous linear GBCA administration with/without macrocyclic 
GBCA administration, were significantly higher than those of non-GBCA group. On T1-weighted images, 
previous reports have showed the strong association between the hyperintensity in the DN and linear GBCA,3 
our result of this study could reinforce the previous result. 
 Gadolinium deposition in DN has been correlated with the number of times of linear GBCA 
administration as reported in the literature.1-3,5 Our study showed that susceptibility values in DN correlated 
less well with the number of times of linear GBCA administration than T1 ratios did. One reason for the 
weaker correlation between susceptibility and the number of times of linear GBCA administration is the 
endogenous substances causing susceptibility changes in DN cause less T1 shortening effect and vary in 
individuals; in addition, the normal range of the susceptibility values in DN is quite wide and can be affected 
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by the variation of age in the group. Relaxivities (R1 and R2) of GBCA is 3 - 5 L/mM/s range and T1 relaxation 
time of brain tissue is relatively long in contrast to T2 relaxation time of brain tissue, therefore, deposition of 
gadolinium will effectively cause T1 shortening effect. In spite of predominance of T1 shortening effect, 
significant susceptibility changes associated putative gadolinium deposition in GBCA group were 
demonstrated in this study. Moreover, the QSM showed wider variation in DN. Therefore this wider variation 
of susceptibility values in DN could be the reason for weaker correlation between susceptibility values and 
the number of times of GBCA administrations. 
 In a prior postmortem study, iron content varied with age in the globus pallidus, caudate nucleus, and 
putamen29 and on MR images DN showed various signal intensity,31 specifically, susceptibility values of DN 
also could change due to iron deposition with aging and this have been reported in the recent study using 
QSM.32,33 In our study, the result of Spearman rank correlation coefficient between susceptibility values in 
DN and subjects’ age showed weak but significant correlation that were consistent with previous studies.32,33 
Nevertheless, in a short time window (e.g. 2-3 years) when age-related changes are negligible, QSM provides 
a means to quantitatively monitor GBCA deposition in DN longitudinally because of its quantitative nature 
and high sensitivity to GBCA.  
 This retrospective study of QSM and gadolinium deposition in DN presents several limitations. First, 
to assess the deposition of gadolinium in DN correctly, sequential prospective study should be needed. In this 
study, consecutive evaluation of susceptibility values and T1 ratios was not performed. Macrocyclic GBCA 
was reported to be low gadolinium deposition in contrast to linear GBCA, and linear GBCA is avoided to use 
today because of the risk of NSF, therefore, it is difficult to plan a prospective comparison study between 
macrocyclic and linear GBCA in human subjects. Second, the number of times of GBCA administration were 
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explored on medical charts as much as possible, but some patients with long-term follow-up in GBCA group 
might have some additional GBCA administration at outside hospitals which were not counted in number of 
times of GBCA administration. Third, globus pallidus was not included for evaluation in this study. Several 
papers revealed relatively higher signal on T1-weighted image probably due to gadolinium deposition 2 6 5, 
however, the signal increase on T1-weighted image was much smaller than that of dentate nucleus. In addition, 
physiological iron accumulation is frequently seen in globus pallidus 29, therefore, we solely focused the 
susceptibility change in the dentate nucleus. 
In conclusion, the susceptibility values in DN after serial GBCA administrations were significantly 
higher in comparison with healthy volunteers. This fact was comparison with our initial hypothesis that 
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TABLE 1  
 
   
Subjects Characteristics  
Parameter GBCA group non-GBCA group 
Total no. of subjects 48 48 
Age (years ± standard deviation) 49.6 ± 15.1* 46.3 ± 21.9* 
Sex (M : F) (23 : 25) (32 : 16) 
   
History of brain surgery  42 0 
History of chemotherapy 29 0 
History of radiation therapy 28 0 
Diagnosis   
  High grade glioma 18 0 
  Low grade glioma 15 0 
  Tumors other than glioma 15** 0 
   
No. of contrast-enhanced MR imaging examination 9.5 (4.75 -21)*** 0 
  No. of linear GBCAs administration 5 (1 – 12.25)*** 0 
  No. of macrocyclic GBCAs administration 4 (1 - 7)*** 0 
* Mean ± standard deviation  
** Meningioma 8, hemangiopericytoma 1, PPTID 1, dermoid 1, colloid 1, cavernous angioma 2, schwannoma 
1. 
*** Median (25th-75th percentile) 






Figure 1.  
Axial images in a 71-year-old woman with left-temporal-lobe glioblastoma who had underwent seven times 
of macrocyclic GBCA and 22 times of linear GBCA administrations (a, b). DN showed a high susceptibility 
value on QSM (a) and hyperintensity on T1-weighted images (b). Axial images in a 30-year-old man with 
right-frontal-lobe glioblastoma who had underwent eleven times of macrocyclic GBCA and 31 times of linear 
GBCA administrations (c, d). DN showed a high susceptibility value on QSM (c) and hyperintensity on T1-
weighted images (d). Axial images in a 28-year-old man without any GBCA administration (e, f). The DN 
showed a less susceptibility value on QSM (e) and did not show hyperintensity on T1-weighted images (f). 
 
Figure 2.  
Graph of the mean susceptibility value difference between GBCA group, who had had serial GBCA 
administrations, and non-GBCA group, who had had no GBCA administration. Susceptibility values at DN in 
GBCA group were significantly higher than those in non-GBCA group (P < 0.0001). Note that error bars 
represent the 95% confidence intervals. 
 
Figure 3. 
Graph of the mean T1 ratio (signal ratio of dentate nucleus/cerebellum cortex on T1-weighted images) 
differences between GBCA group and non-GBCA group. T1 ratios in GBCA group were also significantly 




Figure 4.  
Graph shows result of scattered plots and Spearman rank correlation coefficient between susceptibility values 
at DN in GBCA group and linear GBCA administrations.  
 
Figure 5.  
Graph shows result of scattered plots and Spearman rank correlation coefficient between T1 ratios of DN on 
T1-weighted images in GBCA group and the number of linear GBCA administrations.  
 
Figure 6.  
Graph shows result of scattered plots and Spearman rank correlation coefficient between T1 ratios and 
susceptibility values at DN.  
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